The Role of Myo-Inositol in the regulation of female hormones and Polycystic Ovary Syndrome
Article Sidebar
Main Article Content
Abstract
Inositols are hexahydroxycyclohexanes formed by nine stereoisomers, most of them biologically active. The present review aims to recapitulate the main effects of myo-inositol (MI) on the pathological characteristics of polycystic ovary syndrome (PCOS) and its role as a regulator of the female hormonal and biochemical response. Patients with PCOS present clinical, hormonal, metabolic and physiological disorders that require specialized long-term treatment. For its part, inositol has been shown to be effective in reducing the severity of symptoms, regulating menstrual function, and improving the hormonal profile by controlling metabolic parameters, so its administration represents an effective option for the management of symptoms. of PCOS. Despite this, there are limitations in the studies such as, being a syndrome, PCOS is a heterogeneous condition with a wide variety of symptoms and clinical manifestations, which is why it also implies a variety of responses in patients to MY treatment. In recent years, their research has generated promising therapeutic evidence, but there is still a need to cover more controlled and double-blind studies to define its effect according to PCOS phenotypes, as well as long-term research that evaluates the safety and effectiveness of the treatment over periods of time. Prolonged. In general, MI represents an effective and safe alternative for the treatment of PCOS, showing results like those presented by other treatments without the presence of known side effects.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Los autores conservan los derechos de autor y ceden a la revista el derecho de la primera publicación y pueda editarlo, reproducirlo, distribuirlo, exhibirlo y comunicarlo en el país y en el extranjero mediante medios impresos y electrónicos. Asimismo, asumen el compromiso sobre cualquier litigio o reclamación relacionada con derechos de propiedad intelectual, exonerando de responsabilidad a la Editorial Tecnológica de Costa Rica. Además, se establece que los autores pueden realizar otros acuerdos contractuales independientes y adicionales para la distribución no exclusiva de la versión del artículo publicado en esta revista (p. ej., incluirlo en un repositorio institucional o publicarlo en un libro) siempre que indiquen claramente que el trabajo se publicó por primera vez en esta revista.
References
P. Merviel et al., «Impact of myo-inositol treatment in women with polycystic ovary syndrome in assisted reproductive technologies», Reprod. Health, vol. 18, n.o 1, p. 13, ene. 2021, doi: 10.1186/s12978-021-01073-3.
D. R. Chhetri, «Myo-Inositol and Its Derivatives: Their Emerging Role in the Treatment of Human Diseases», Front. Pharmacol., vol. 10, 2019, Accedido: 2 de octubre de 2023. [En línea]. Disponible en: https://www.frontiersin.org/articles/10.3389/fphar.2019.01172
Z. Kamenov y A. Gateva, «Inositols in PCOS», Molecules, vol. 25, n.o 23, Art. n.o 23, ene. 2020, doi: 10.3390/molecules25235566.
I. O. Carmona-Ruiz et al., «Mioinositol en combinación con D-chiro-inositol: resultados preliminares en el tratamiento de primera línea de pacientes con síndrome de ovario poliquístico», Ginecología y obstetricia de México, vol. 85, n.o 3, pp. 141-151, 2017.
I. (Tai-L. Lee, Y.-F. Chang, F. Choi, y A. Bodemer, «Inositol in Dermatologic Diseases», Acad. J. Health Sci. Med. Balear, vol. 38, n.o 1, pp. 29-38, 2023.
K. Y. Su et al., «Vasodilators for primary Raynaud’s phenomenon», Cochrane Database Syst. Rev., n.o 5, 2021, doi: 10.1002/14651858.CD006687.pub4.
W. F. Jackson, «Calcium-Dependent Ion Channels and the Regulation of Arteriolar Myogenic Tone», Front. Physiol., vol. 12, 2021, Accedido: 1 de octubre de 2023. [En línea]. Disponible en: https://www.frontiersin.org/articles/10.3389/fphys.2021.770450
L. J. Lucca, R. M. A. Moysés, y A. S. Lima Neto, «Diagnóstico e tratamento da calcifilaxia de pacientes com doença renal crônica», Braz. J. Nephrol., vol. 43, pp. 665-668, dic. 2021, doi: 10.1590/2175-8239-JBN-2021-S111.
J. Perelló, P. h. Joubert, M. d. Ferrer, A. z. Canals, S. Sinha, y C. Salcedo, «First-time-in-human randomized clinical trial in healthy volunteers and haemodialysis patients with SNF472, a novel inhibitor of vascular calcification», Br. J. Clin. Pharmacol., vol. 84, n.o 12, pp. 2867-2876, 2018, doi: 10.1111/bcp.13752.
S. Roseff y M. Montenegro, «Inositol Treatment for PCOS Should Be Science-Based and Not Arbitrary», Int. J. Endocrinol., vol. 2020, p. e6461254, mar. 2020, doi: 10.1155/2020/6461254.
T. Cantelmi y C. Di Lorenzo, «Chapter 6 - Myo-inositol could restore peripheral inositol depletion induced by treatments for psychiatric and neurological conditions», en A Clinical Guide to Inositols, V. Unfer y D. Dewailly, Eds., Academic Press, 2023, pp. 73-85. doi: 10.1016/B978-0-323-91673-8.00003-0.
S. Dinicola et al., «Inositol induces mesenchymal-epithelial reversion in breast cancer cells through cytoskeleton rearrangement», Exp. Cell Res., vol. 345, n.o 1, pp. 37-50, jul. 2016, doi: 10.1016/j.yexcr.2016.05.007.
S. Cowan et al., «Lifestyle management in polycystic ovary syndrome – beyond diet and physical activity», BMC Endocr. Disord., vol. 23, n.o 1, p. 14, ene. 2023, doi: 10.1186/s12902-022-01208-y.
X.-J. Shi, Y. Du, L. Chen, Y.-Y. Chen, M. Luo, y Y. Cheng, «Treatment of polycystic ovary syndrome and its associated psychiatric symptoms with the Mongolian medicine Nuangong Qiwei Pill and macelignan», J. Ethnopharmacol., vol. 317, p. 116812, dic. 2023, doi: 10.1016/j.jep.2023.116812.
M. L. Croze y C. O. Soulage, «Potential role and therapeutic interests of myo-inositol in metabolic diseases», Biochimie, vol. 95, n.o 10, pp. 1811-1827, oct. 2013, doi: 10.1016/j.biochi.2013.05.011.
G. Carlomagno, M. Nordio, T. T. Chiu, y V. Unfer, «Contribution of myo-inositol and melatonin to human reproduction», Eur. J. Obstet. Gynecol. Reprod. Biol., vol. 159, n.o 2, pp. 267-272, dic. 2011, doi: 10.1016/j.ejogrb.2011.07.038.
R. M. Deranieh y M. L. Greenberg, «Cellular consequences of inositol depletion», Biochem. Soc. Trans., vol. 37, n.o 5, pp. 1099-1103, sep. 2009, doi: 10.1042/BST0371099.
P. H. Meng et al., «Crosstalks between Myo-Inositol Metabolism, Programmed Cell Death and Basal Immunity in Arabidopsis», PLOS ONE, vol. 4, n.o 10, p. e7364, oct. 2009, doi: 10.1371/journal.pone.0007364.
F. Eisenberg y A. H. Bolden, «Biosynthesis of inositol in rat testis homogenate», Biochem. Biophys. Res. Commun., vol. 12, n.o 1, pp. 72-77, jul. 1963, doi: 10.1016/0006-291X(63)90416-9.
G. Hauser y V. N. Finelli, «The Biosynthesis of Free and Phosphatide Myo-inositol from Glucose by Mammalian Tissue Slices», J. Biol. Chem., vol. 238, n.o 10, pp. 3224-3228, oct. 1963, doi: 10.1016/S0021-9258(18)48650-4.
S. Eivazi et al., «The hormone-sensitive lipase C-60G polymorphism is correlated with recurrent spontaneous abortion in women with polycystic ovary syndrome», Gene Rep., vol. 32, p. 101788, sep. 2023, doi: 10.1016/j.genrep.2023.101788.
C. Brutocao, F. Zaiem, M. Alsawas, A. S. Morrow, M. H. Murad, y A. Javed, «Psychiatric disorders in women with polycystic ovary syndrome: a systematic review and meta-analysis», Endocrine, vol. 62, n.o 2, pp. 318-325, nov. 2018, doi: 10.1007/s12020-018-1692-3.
T. T. Y. Chiu, M. S. Rogers, E. L. K. Law, C. M. Briton-Jones, L. P. Cheung, y C. J. Haines, «Follicular fluid and serum concentrations of myo-inositol in patients undergoing IVF: relationship with oocyte quality», Hum. Reprod., vol. 17, n.o 6, pp. 1591-1596, jun. 2002, doi: 10.1093/humrep/17.6.1591.
A. Alinezhad y F. Jafari, «The relationship between components of metabolic syndrome and plasma level of sex hormone-binding globulin», Eur. J. Transl. Myol., vol. 29, n.o 2, p. 8196, jun. 2019, doi: 10.4081/ejtm.2019.8196.
P. Merviel et al., «Impact of myo-inositol treatment in women with polycystic ovary syndrome in assisted reproductive technologies», Reprod. Health, vol. 18, n.o 1, p. 13, ene. 2021, doi: 10.1186/s12978-021-01073-3.
N. O. Francone, T. Ramirez, y C. E. Boots, «Contemporary Management of the Patient with Polycystic Ovary Syndrome», Obstetrics and Gynecology Clinics of North America, sep. 2023, Dec; 50 (4): 595-705, doi: 10.1016/j.ogc.2023.08.003. Epub 2023 Sep 15. PMID: 37914488.
Q. Liu, Y. Xie, L. Qu, M. Zhang, y Z. Mo, «Dyslipidemia involvement in the development of polycystic ovary syndrome», Taiwan. J. Obstet. Gynecol., vol. 58, n.o 4, pp. 447-453, jul. 2019, doi: 10.1016/j.tjog.2019.05.003.
A. Sokalska, S. D. Stanley, J. A. Villanueva, I. Ortega, y A. J. Duleba, «Comparison of effects of different statins on growth and steroidogenesis of rat ovarian theca-interstitial cells», Biol Reprod, vol. 90, n.o 2, p. 44, feb. 2014, doi: 10.1095/biolreprod.113.114843.
N. Ferri y A. Corsini, «Clinical evidence of statin therapy in non-dyslipidemic disorders», Pharmacol. Res., vol. 88, pp. 20-30, oct. 2014, doi: 10.1016/j.phrs.2014.02.003.
S. Dinicola, T. T. Y. Chiu, V. Unfer, G. Carlomagno, y M. Bizzarri, «The rationale of the myo-inositol and D-chiro-inositol combined treatment for polycystic ovary syndrome», J. Clin. Pharmacol., vol. 54, n.o 10, pp. 1079-1092, 2014, doi: 10.1002/jcph.362.
L. Pal, S. Jindal, B. R. Witt, y N. Santoro, «Less is more: increased gonadotropin use for ovarian stimulation adversely influences clinical pregnancy and live birth after in vitro fertilization», Fertil. Steril., vol. 89, n.o 6, pp. 1694-1701, jun. 2008, doi: 10.1016/j.fertnstert.2007.05.055.
P. G. Artini et al., «Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study», Gynecol. Endocrinol., vol. 29, n.o 4, pp. 375-379, abr. 2013, doi: 10.3109/09513590.2012.743020.
Z. Kamenov, G. Kolarov, A. Gateva, G. Carlomagno, y A. D. Genazzani, «Ovulation induction with myo-inositol alone and in combination with clomiphene citrate in polycystic ovarian syndrome patients with insulin resistance», Gynecol. Endocrinol., vol. 31, n.o 2, pp. 131-135, feb. 2015, doi: 10.3109/09513590.2014.964640.
V. Unfer, F. Facchinetti, B. Orrù, B. Giordani, y J. Nestler, «Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials», Endocr. Connect., vol. 6, n.o 8, pp. 647-658, sep. 2017, doi: 10.1530/EC-17-0243.
J. J. DiNicolantonio y J. H. O’Keefe, «Myo-inositol for insulin resistance, metabolic syndrome, polycystic ovary syndrome and gestational diabetes», Open Heart, vol. 9, n.o 1, p. e001989, mar. 2022, doi: 10.1136/openhrt-2022-001989.
H. Zhao, C. Xing, J. Zhang, y B. He, «Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis», Reprod. Health, vol. 18, n.o 1, p. 171, ago. 2021, doi: 10.1186/s12978-021-01207-7.
A. S. Laganà, A. Vitagliano, M. Noventa, G. Ambrosini, y R. D’Anna, «Myo-inositol supplementation reduces the amount of gonadotropins and length of ovarian stimulation in women undergoing IVF: a systematic review and meta-analysis of randomized controlled trials», Arch. Gynecol. Obstet., vol. 298, n.o 4, pp. 675-684, oct. 2018, doi: 10.1007/s00404-018-4861-y.
L. Pkhaladze, V. Unfer, y D. Dewailly, «Chapter 10 - Use of myo-inositol in the treatment of PCOS symptoms in adolescents», en A Clinical Guide to Inositols, V. Unfer y D. Dewailly, Eds., Academic Press, 2023, pp. 151-165. doi: 10.1016/B978-0-323-91673-8.00001-7.
V. Unfer, G. Monastra, M. Tilotta, G. Forte, y S. Dinicola, «Chapter 11 - Inositols and other supplements in the management of PCOS», en Polycystic Ovary Syndrome, E. Diamanti-Kandarakis, Ed., Elsevier, 2022, pp. 167-186. doi: 10.1016/B978-0-12-823045-9.00014-6.
D. Greff et al., «Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials», Reprod. Biol. Endocrinol., vol. 21, n.o 1, p. 10, ene. 2023, doi: 10.1186/s12958-023-01055-z.
L. Barrea, L. Verde, C. Vetrani, S. Savastano, A. Colao, y G. Muscogiuri, «Chronotype: A Tool to Screen Eating Habits in Polycystic Ovary Syndrome?», Nutrients, vol. 14, n.o 5, Art. n.o 5, ene. 2022, doi: 10.3390/nu14050955.
R. Bodepudi et al., «Myoinositol Versus Metformin in the Treatment of Polycystic Ovarian Syndrome: A Systematic Review», Cureus, vol. 15, n.o 7, p. e41748, jul. 2023, doi: 10.7759/cureus.41748.